Cancer Immunotherapy - Global Market Outlook (2017-2023)

Cancer Immunotherapy - Global Market Outlook (2017-2023)

  • Published: December 2017
  • ID: SMRC16891

According to Stratistics MRC, the Global Cancer Immunotherapy market is estimated at $62.57 billion in 2016 and is expected to reach $160.24 billion by 2023 growing at a CAGR of 14.3% from 2016 to 2023. Rapid increase in cases of cancer across the globe, technical advancement in treatment therapies, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment and lack of awareness are the restraints hampering the market. On the other hand rise in clinical trials against different cancers in immunotherapy and elevated expansion prediction in developing countries are some opportunities for the market over the forecast period.

Based on product, the monoclonal antibodies are made by single clone of cells or cell line and are comprised of identical antibody molecules. The factors such as growing occurrence of cancer and other chronic diseases, rising awareness among patients and rising requirement for personalized medicine are favoring this product’s segment.

In terms of geography, North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the market include Bristol-Myers Squibb, F. Hoffmann-LA Roche Ltd, GlaxoSmithKline, Pfizer, Eli Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Amgen Inc., Biovest International Inc, Ablynx NV, Genentech Inc, Bellicum Pharmaceuticals Inc, Bayer AG, Oxford BioTherapeutics Ltd., Merck, Sydys Corporation, Dendreon, Xencor, Daiichi Sankyo and TG Therapeutics.

Product Types Covered:
• Immune Checkpoint Inhibitors 
• Cancer Monoclonal Antibodies 
• Immunomodulators 
• Cancer Vaccines  
• Cell Therapies 

Cancer Types Covered:
• Breast Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Multiple Myeloma
• Melanoma
• Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Other Cancer Types

End Users Covered:
• Hospital
• Clinics
• Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan       
    • China       
    • India       
    • Australia 
    • New Zealand     
    • South Korea      
    • Rest of Asia Pacific   
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary        
          
2 Preface 
        
 2.1 Abstract        
 2.2 Stake Holders       
 2.3 Research Scope       
 2.4 Research Methodology      
  2.4.1 Data Mining      
  2.4.2 Data Analysis      
  2.4.3 Data Validation      
  2.4.4 Research Approach      
 2.5 Research Sources       
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions      
          
3 Market Trend Analysis       
 3.1 Introduction       
 3.2 Drivers        
 3.3 Restraints       
 3.4 Opportunities       
 3.5 Threats        
 3.6 Product Analysis       
 3.7 End User Analysis       
 3.8 Emerging Markets       
 3.9 Futuristic Market Scenario      
          
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry       
          
5 Global Cancer Immunotherapy Market, By Product Type     
 5.1 Introduction        
 5.2 Immune Checkpoint Inhibitors     
  5.2.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)  
  5.2.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) 
 5.3 Cancer Monoclonal Antibodies     
  5.3.1 Conjugated Monoclonal Antibodies    
  5.3.2 Bispecific Monoclonal Antibodies    
  5.3.3 Naked Monoclonal Antibodies     
 5.4 Immunomodulators       
  5.4.1 Oncolytic Virus      
   5.4.1.1 Immunity as an Obstacle    
   5.4.1.2 Immunotherapy     
   5.4.1.3 Approved Products & Clinical Trails   
   5.4.1.4 Immunity as an Ally     
  5.4.2 Interleukins (IL)      
  5.4.3 Interferons (IFN)      
 5.5 Cancer Vaccines        
  5.5.1 Prophylactic Vaccines     
  5.5.2 Therapeutic Vaccines     
 5.6 Cell Therapies       
  5.6.1 Chimeric Antigen Receptor (CAR) T Cell Therapy   
  5.6.2 Dendritic Cells      
          
6 Global Cancer Immunotherapy market, By Cancer Type    
 6.1 Introduction        
 6.2 Breast Cancer       
 6.3 Colorectal Cancer       
 6.4 Head & Neck Cancer      
 6.5 Multiple Myeloma        
 6.6 Melanoma       
 6.7 Lung Cancer       
 6.8 Prostate Cancer       
 6.9 Ovarian Cancer       
 6.10 Pancreatic Cancer       
 6.11 Other Cancer Types       
          
7 Global Cancer Immunotherapy market, By End User      
 7.1 Introduction        
 7.2 Hospital        
 7.3 Clinics         
 7.4 Other End Users       
          
8 Global Cancer Immunotherapy Market, By Geography    
 8.1 Introduction        
 8.2 North America       
  8.2.1 US       
  8.2.2 Canada       
  8.2.3 Mexico       
 8.3 Europe        
  8.3.1 Germany        
  8.3.2 U.K.       
  8.3.3 Italy       
  8.3.4 France       
  8.3.5 Spain        
  8.3.6 Rest of Europe      
 8.4 Asia Pacific       
  8.4.1 Japan       
  8.4.2 China       
  8.4.3 India       
  8.4.4 Australia       
  8.4.5 New Zealand      
  8.4.6 South Korea      
  8.4.7 Rest of Asia Pacific      
 8.5 South America       
  8.5.1 Argentina      
  8.5.2 Brazil       
  8.5.3 Chile       
  8.5.4 Rest of South America     
 8.6 Middle East & Africa      
  8.6.1 Saudi Arabia      
  8.6.2 UAE       
  8.6.3 Qatar       
  8.6.4 South Africa      
  8.6.5 Rest of Middle East & Africa     
          
9 Key Developments        
 9.1 Agreements, Partnerships, Collaborations and Joint Ventures   
 9.2 Acquisitions & Mergers      
 9.3 New Product Launch      
 9.4 Expansions       
 9.5 Other Key Strategies      
          
10 Company Profiling        
 10.1 Bristol-Myers Squibb       
 10.2 F. Hoffmann-LA Roche Ltd       
 10.3 GlaxoSmithKline        
 10.4 Pfizer         
 10.5 Eli Lilly and Company       
 10.6 Janssen Global Services, LLC (Johnson and Johnson)    
 10.7 Novartis         
 10.8 Amgen Inc.        
 10.9 Biovest International Inc       
 10.10 Ablynx NV        
 10.11 Genentech Inc        
 10.12 Bellicum Pharmaceuticals Inc       
 10.13 Bayer AG         
 10.14 Oxford BioTherapeutics Ltd.       
 10.15 Merck         
 10.16 Sydys Corporation       
 10.17 Dendreon       
 10.18 Xencor        
 10.19 Daiichi Sankyo       
 10.20 TG Therapeutics       


List Of Tables         
1 Global Cancer Immunotherapy Market Outlook, By Region (2014-2023) ($MN)  
2 Global Cancer Immunotherapy Market Outlook, By Product Type (2014-2023) ($MN) 
3 Global Cancer Immunotherapy Market Outlook, By Immune Checkpoint Inhibitors (2014-2023) ($MN)
4 Global Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2014-2023) ($MN)
5 Global Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2014-2023) ($MN)
6 Global Cancer Immunotherapy Market Outlook, By Cancer Monoclonal Antibodies (2014-2023) ($MN)
7 Global Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2014-2023) ($MN)
8 Global Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2014-2023) ($MN)
9 Global Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2014-2023) ($MN)
10 Global Cancer Immunotherapy Market Outlook, By Immunomodulators (2014-2023) ($MN) 
11 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2014-2023) ($MN) 
12 Global Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2014-2023) ($MN) 
13 Global Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2014-2023) ($MN) 
14 Global Cancer Immunotherapy Market Outlook, By Cancer Vaccines  (2014-2023) ($MN) 
15 Global Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2014-2023) ($MN) 
16 Global Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2014-2023) ($MN) 
17 Global Cancer Immunotherapy Market Outlook, By Cell Therapies (2014-2023) ($MN) 
18 Global Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2014-2023) ($MN)
19 Global Cancer Immunotherapy Market Outlook, By Dendritic Cells (2014-2023) ($MN) 
20 Global Cancer Immunotherapy Market Outlook, By Cancer Type (2014-2023) ($MN)  
21 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2014-2023) ($MN) 
22 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2014-2023) ($MN) 
23 Global Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2014-2023) ($MN) 
24 Global Cancer Immunotherapy Market Outlook, By Multiple Myeloma  (2014-2023) ($MN) 
25 Global Cancer Immunotherapy Market Outlook, By Melanoma (2014-2023) ($MN)  
26 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2014-2023) ($MN)  
27 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2014-2023) ($MN) 
28 Global Cancer Immunotherapy Market Outlook, By Ovarian Cancer (2014-2023) ($MN) 
29 Global Cancer Immunotherapy Market Outlook, By Pancreatic Cancer (2014-2023) ($MN) 
30 Global Cancer Immunotherapy Market Outlook, By Other Cancer Types (2014-2023) ($MN) 
31 Global Cancer Immunotherapy Market Outlook, By End User  (2014-2023) ($MN)  
32 Global Cancer Immunotherapy Market Outlook, By Hospital (2014-2023) ($MN)  
33 Global Cancer Immunotherapy Market Outlook, By Clinics  (2014-2023) ($MN)  
34 Global Cancer Immunotherapy Market Outlook, By Other End Users (2014-2023) ($MN) 
          

Note: Tables for North America, Europe, APAC, South America and Middle East & Africa Regions are also represented in the same manner as above

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials